The activities of REV3 and REV1 have been linked to the drug resistance to cisplatin and cyclophosphamide in murine models of both B-cell lymphoma and lung cancer[23,25]. The gene discussed is REV3L; the disease is B-cell non-Hodgkin lymphoma.